Prostate cancer remains the most common cancer in men, accounting for more than 20% of incident cancer cases in US men in 2022.1 In 2012, the US Preventive Services Task Force recommended against routine prostate-specific antigen (PSA) screening owing to risk of overdiagnosis of clinically insignificant prostate cancer. This evidence concerns the gene KLK3 and prostate carcinoma.